BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCRX BioCryst制药

已收盘 08-12 16:00:00 EDT

10.59

+0.25

+2.42%

盘后10.51

-0.08-0.76%

19:59 EDT

最高10.68	最低10.10	成交量386.56万
今开10.33	昨收10.34	日振幅5.61%
总市值27.06亿	流通市值23.09亿	总股本2.56亿
成交额4,053万	换手率1.77%	流通股本2.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"BioCryst制药","latestPrice":10.59,"timestamp":1786564800000,"preClose":10.34,"halted":0,"volume":3865576,"hourTrading":{"tag":"盘后","latestPrice":10.51,"preClose":10.59,"latestTime":"19:59 EDT","volume":40956,"amount":433677.7577,"timestamp":1786579187340,"change":-0.08,"changeRate":-0.007554,"amplitude":0.007554},"delay":0,"changeRate":0.024177949709864605,"floatShares":218000000,"shares":255535105,"eps":-1.5053626,"marketStatus":"已收盘","change":0.25,"latestTime":"08-12 16:00:00 EDT","open":10.33,"high":10.68,"low":10.1,"amount":40526868.869344,"amplitude":0.056093,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.5053626,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786608000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":10.34,"preHourTrading":{"tag":"盘前","latestPrice":10.33,"preClose":10.34,"latestTime":"09:28 EDT","volume":4593,"amount":48047.134164,"timestamp":1786541280121,"change":-0.01,"changeRate":-0.000967,"amplitude":0.023211},"postHourTrading":{"tag":"盘后","latestPrice":10.51,"preClose":10.59,"latestTime":"19:59 EDT","volume":40956,"amount":433677.7577,"timestamp":1786579187340,"change":-0.08,"changeRate":-0.007554,"amplitude":0.007554},"volumeRatio":0.819923,"impliedVol":0.7243,"impliedVolPercentile":0.745},"requestUrl":"/m/hq/s/BCRX/tweets","defaultTab":"tweets","newsList":[{"id":"1166404862","title":"BioCryst制药：截至2026年6月30日，现金、现金等价物、受限现金及投资共计3.54亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166404862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166404862?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:35","pubTimestamp":1785929756,"startTime":"0","endTime":"0","summary":"BioCryst制药披露，截至2026年6月30日，公司持有的现金、现金等价物、受限现金以及投资总额达到了3.54亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188476991","title":"BioCryst制药预计关闭研发中心将产生额外费用；分析工作仍在进行中——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1188476991","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188476991?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:19","pubTimestamp":1785842353,"startTime":"0","endTime":"0","summary":"BioCryst制药（BioCryst Pharmaceuticals）在提交给美国证券交易委员会（SEC）的文件中透露，该公司预期其位于研发中心的关闭行动将引发额外成本。目前，关于这些费用的具体数额及影响的分析工作仍在持续进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119069762","title":"BioCryst制药：SEC文件披露一次性遣散费约620万至750万美元，现金支出约530万至660万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119069762","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119069762?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:19","pubTimestamp":1785842349,"startTime":"0","endTime":"0","summary":"BioCryst制药（BioCryst Pharmaceuticals）在向美国证券交易委员会（SEC）提交的文件中透露，预计将产生约620万至750万美元的一次性遣散费用。与此同时，该公司预计将支付约530万至660万美元的现金。这些数字反映的是与员工终止福利相关的成本。该公司的估算基于当前的重组计划，具体金额可能有所调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4139","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123716883","title":"财报前瞻｜BioCryst制药本季度营收预计增21.89%，机构多头占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1123716883","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123716883?lang=zh_cn&edition=full","pubTime":"2026-07-29 14:12","pubTimestamp":1785305552,"startTime":"0","endTime":"0","summary":"BioCryst制药将于2026年08月05日发布最新季度财报，市场关注产品放量、成本收缩与外部授权对单季盈利能力的共同影响。市场一致预期本季度BioCryst制药营收约1.83亿美元，同比增长21.89%；调整后每股收益0.12美元，同比增长746.86%；当前一致预期未给出单季毛利率与净利率的明确区间，公司层面亦无分季度的净利润或净利率指引。根据近期针对BioCryst制药的多篇分析评论与快评，看多观点占据主导。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜BioCryst制药本季度营收预计增21.89%，机构多头占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129911416","title":"BioCryst制药宣布将于2026年底前关闭伯明翰发现中心并终止内部发现项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1129911416","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129911416?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:01","pubTimestamp":1782730880,"startTime":"0","endTime":"0","summary":"BioCryst制药公司决定，在2026年年底前，其位于伯明翰的发现中心将停止运营，同时公司内部的药物发现项目也将全部终止。这一战略调整标志着公司研发重心的转移。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128405872","title":"BioCryst制药在2026年欧洲过敏与临床免疫学会年会上展示新临床数据与现实证据，彰显Hae产品组合影响力","url":"https://stock-news.laohu8.com/highlight/detail?id=1128405872","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128405872?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:01","pubTimestamp":1781262075,"startTime":"0","endTime":"0","summary":"BioCryst制药在2026年欧洲过敏与临床免疫学会年度会议上公布了其Hae产品组合的最新临床数据与现实世界证据，突显了该系列产品在相关治疗领域的显著影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136188200","title":"BioCryst制药维持2026财年非GAAP运营支出指引于4.5亿至4.7亿美元区间","url":"https://stock-news.laohu8.com/highlight/detail?id=1136188200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136188200?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:10","pubTimestamp":1778065847,"startTime":"0","endTime":"0","summary":"BioCryst制药公司近日重申了其2026财年的财务展望，确认非美国通用会计准则下的运营支出指引仍维持在4.5亿美元至4.7亿美元之间。这一预算框架反映了公司对研发投入与成本管控的平衡策略。\n在当前生物科技行业融资环境充满挑战的背景下，明确的支出指引有助于稳定投资者预期。该预算区间将为公司核心管线的临床推进及商业化活动提供资金支持，同时保持财务纪律性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126328796","title":"BioCryst制药与Neopharmed Gentili爱尔兰附属公司就遗传性血管水肿药物Navenibart达成欧洲授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1126328796","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126328796?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:06","pubTimestamp":1777892768,"startTime":"0","endTime":"0","summary":"BioCryst制药宣布，已与Neopharmed Gentili的爱尔兰附属公司签署了一项授权协议，涉及遗传性血管水肿治疗药物Navenibart在欧洲地区的权益。该合作标志着BioCryst在拓展其核心产品全球市场布局方面迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138827449","title":"BioCryst制药：Navenibart三期临床试验项目按计划推进，预计2027年底前向美国提交监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1138827449","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138827449?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:02","pubTimestamp":1777892535,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc (BCRX) 宣布，其核心候选药物Navenibart的三期临床试验项目正稳步推进，公司预计将在2027年底前向美国食品药品监督管理局（FDA）提交监管申请。\n该项目目前进展顺利，各项时间节点均符合预期。Navenibart作为一种在研疗法，其临床开发计划正按既定战略执行。此次三期临床试验的顺利推进，标志着该药物向最终获批上市迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104716053","title":"财报前瞻｜BioCryst制药本季度营收预计增19.12%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1104716053","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104716053?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:41","pubTimestamp":1777448504,"startTime":"0","endTime":"0","summary":"BioCryst制药将于2026年05月06日美股盘前发布最新季度财报，市场聚焦核心产品动能与盈利质量。上季度BioCryst制药营收为1.63亿美元，同比增长23.60%；毛利率为88.11%；归属于母公司股东的净利润为2.46亿美元；净利率为60.47%；调整后每股收益为0.01美元，同比增长107.69%。基于近期追踪的公开信息，在参与覆盖BioCryst制药的9家机构中，看多与“买入”建议合计占比100%，显示机构观点偏向积极。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜BioCryst制药本季度营收预计增19.12%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105528475","title":"BioCryst制药任命Sandeep M. Menon为首席研发官","url":"https://stock-news.laohu8.com/highlight/detail?id=1105528475","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105528475?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:04","pubTimestamp":1775473445,"startTime":"0","endTime":"0","summary":"经验丰富的研发领导者Sandeep M. Menon博士加入BioCryst制药，其职业生涯以推动创新疗法从早期开发走向全球获批而著称。BioCryst制药近日宣布，任命医学博士、哲学博士Sandeep M. Menon为首席研发官。凭借ORLADEYO的商业成功，以及近期对Astria Therapeutics及其navenibart项目的收购，BioCryst正步入战略执行的新阶段，旨在通过罕见病疗法的开发和商业化来构建价值。Menon博士从Alnylam制药公司加入BioCryst，此前他在该公司担任首席开发官，负责监督跨越多个治疗领域的广泛产品组合的全球临床开发与安全事务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4555","BK4588","BK4232","BCRX","BK4585","ICON","BK4604","R","BK4139","BK4547","BK4022","TM","BK4021","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169981618","title":"异动解读 | BioCryst制药盘前大涨5.3%，因重申奥拉迪约全年收入指引显信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1169981618","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169981618?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:08","pubTimestamp":1772111290,"startTime":"0","endTime":"0","summary":"BioCryst制药今日盘前股价大涨5.30%，引起了投资者的密切关注。消息面上，BioCryst制药公司重申了其对2026财年旗下药物奥拉迪约（Orladeyo）全球净收入的全年业绩指引，这一举动向市场传递了公司对该核心产品未来销售表现的强烈信心，被视为积极的信号，从而提振了股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114954452","title":"BioCryst制药维持2026年奥拉迪约全球净收入全年预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1114954452","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114954452?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:05","pubTimestamp":1772107511,"startTime":"0","endTime":"0","summary":"BioCryst制药公司重申了其对2026财年旗下药物奥拉迪约（Orladeyo）全球净收入的全年业绩指引，显示出公司对该产品未来市场表现的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101332099","title":"财报前瞻｜BioCryst制药本季度营收预计增16.27%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1101332099","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101332099?lang=zh_cn&edition=full","pubTime":"2026-02-19 13:51","pubTimestamp":1771480318,"startTime":"0","endTime":"0","summary":"BioCryst制药将于2026年02月26日发布最新季度财报，市场关注核心品种销售动能与盈利结构变化。市场一致预期BioCryst制药本季度营收约为1.51亿美元，同比增速16.27%；调整后每股收益预计为0.05美元，同比增速184.88%；EBIT预计为2,184.06万美元，同比增速141.86%。BioCryst制药上季度营收为1.59亿美元，同比增长36.14%；毛利率为70.65%；归属于母公司股东的净利润为1,289.90万美元，对应净利率8.09%；调整后每股收益为0.06美元，同比增长185.71%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜BioCryst制药本季度营收预计增16.27%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518731582","title":"BioCryst制药盘中异动 早盘快速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518731582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518731582?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:25","pubTimestamp":1741616747,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时25分，BioCryst制药股票出现波动，股价急速下跌5.01%。截至发稿，该股报7.31美元/股，成交量35.2675万股，换手率0.17%，振幅4.16%。BioCryst制药股票所在的制药行业中，整体跌幅为2.11%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503102225479640433b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503102225479640433b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677559","title":"BioCryst制药盘中异动 早盘快速跳水7.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677559?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098751,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，BioCryst制药股票出现异动，股价快速下跌7.85%。截至发稿，该股报7.87美元/股，成交量23.2054万股，换手率0.11%，振幅4.36%。BioCryst制药股票所在的制药行业中，整体跌幅为0.02%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223231a25f04c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223231a25f04c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516379074","title":"BioCryst制药2024财年实现净利润-88.88百万美元，同比增加60.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516379074?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:00","pubTimestamp":1740758437,"startTime":"0","endTime":"0","summary":"3月1日，BioCryst制药公布财报，公告显示公司2024财年净利润为-88.88百万美元，同比增加60.85%；其中营业收入为4.51亿美元，同比增加36.25%，每股基本收益为-0.43美元。从资产负债表来看，BioCryst制药总负债9.66亿美元，其中短期债务35.45百万美元，资产负债比为0.51，流动比率为2.64。机构评级：截至2025年3月1日，当前有11家机构对BioCryst制药目标价做出预测，其中目标均价为15.91美元，其中最低目标价为8.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000046a25817fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000046a25817fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514056016","title":"Citizens Capital Markets：重申BioCryst Pharma(BCRX.US)评级，由优于大市调整至优于大市评级, 目标价由18.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514056016","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514056016?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:51","pubTimestamp":1740498699,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申BioCryst Pharma(BCRX.US)评级，由优于大市调整至优于大市评级, 目标价由18.00美元调整至18.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25235148385221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173855464","title":"异动解读 | BCRX第四季度业绩疲软引发7.17%盘中大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1173855464","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173855464?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:33","pubTimestamp":1740407637,"startTime":"0","endTime":"0","summary":"BCRX(BioCryst制药)公司周一盘中大跌7.17%,引起市场广泛关注。这一波动与公司近期披露的2024年第四季度财报数据存在一定关联。\n\n数据显示,BCRX在该季度实现营收1.315亿美元,同比增长40.83%,超出市场预期。不过,公司每股收益为-0.13美元,低于分析师预期的-0.06美元,同比亦无改善。\n\n尽管营收增速喜人,但由于净利润持续亏损,加之EPS表现不佳,市场对BCRX未来增长前景的预期可能受到一定打击,进而引发投资者资金流出,促使股价承压下跌。值得关注的是,该公司日后的研发投入及新药上市进程也可能是股价波动的主要驱动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513727313","title":"BioCryst制药盘中异动 股价大跌7.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513727313?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:30","pubTimestamp":1740407451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时30分，BioCryst制药股票出现异动，股价快速下跌7.06%。截至发稿，该股报8.56美元/股，成交量14.0755万股，换手率0.07%，振幅1.50%。BioCryst制药股票所在的生物技术行业中，整体涨幅为0.00%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223052962e982f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223052962e982f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":0.1463},{"period":"1month","weight":-0.0105},{"period":"3month","weight":0.0771},{"period":"6month","weight":0.5206},{"period":"1year","weight":0.261},{"period":"ytd","weight":0.3256}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioCryst Pharmaceuticals, Inc.是一家特拉华州公司，最初成立于1986年。该公司是一家全球性生物技术公司，致力于改善遗传性血管性水肿和罕见病患者的生活。该公司利用结构引导药物设计方面的专业知识，目标是开发一流或一流的口服小分子和注射蛋白疗法，以针对难以治疗的罕见疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.02531},{"month":2,"riseRate":0.53125,"avgChangeRate":-0.000169},{"month":3,"riseRate":0.375,"avgChangeRate":0.017253},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046266},{"month":5,"riseRate":0.545455,"avgChangeRate":0.060211},{"month":6,"riseRate":0.606061,"avgChangeRate":0.030077},{"month":7,"riseRate":0.545455,"avgChangeRate":0.106685},{"month":8,"riseRate":0.606061,"avgChangeRate":0.101241},{"month":9,"riseRate":0.34375,"avgChangeRate":-0.049493},{"month":10,"riseRate":0.5,"avgChangeRate":-0.046955},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.004698}],"exchange":"NASDAQ","name":"BioCryst制药","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioCryst制药(BCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioCryst制药,BCRX,BioCryst制药股票,BioCryst制药股票老虎,BioCryst制药股票老虎国际,BioCryst制药行情,BioCryst制药股票行情,BioCryst制药股价,BioCryst制药股市,BioCryst制药股票价格,BioCryst制药股票交易,BioCryst制药股票购买,BioCryst制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioCryst制药(BCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}